With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
Here's how to get your hands on the hottest clothing, shoes, and accessories launches of 2025, according to our PEOPLE Style ...